VYNT-0126 / Vyant Bio - LARVOL DELTA

Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Vyant Bio

New P2 trial • Developmental Disorders • Movement Disorders

Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year (Proactiveinvestors) - "Vyant is also planning to file an Investigational New Drug Application with the US Food & Drug Administration (FDA) for a pediatric study in 2023....VYNT-0126 to treat Rett Syndrome, into clinical trials early next year based on pre-clinical efficacy data and following encouragement and guidance from the International Rett Syndrome Foundation (IRSF), the company said as it posted second-quarter results.'With our preclinical data with VYNT-0126, which we believe is compelling, we met with the Clinical Trial Committee of the International Rett Syndrome Foundation on July 19, 2022, to receive their feedback and guidance on our plans to conduct a proof-of-concept clinical trial of VYNT-0126 in adult Rett patients in Australia.'"

IND • Preclinical • CNS Disorders